AndtbackaR.H.I., KaufmanH.L., CollichioF.Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.J Clin Oncol2015; 33: 2780–8.
2.
LiuB.L., RobinsonM., HanZ-QICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.Gene Ther2003; 10: 292–303.
3.
HuJ.C.C., CoffinR.S., DavisC.J.A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.Clin Cancer Res2006; 12: 6737–47.
4.
SenzerN.N., KaufmanH.L., AmatrudaT.Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.J Clin Oncol2009; 27: 5763–71.
